How do you manage severe lenalidomide-associated drug rash in a transplant-eligible patient with multiple myeloma?
Would your approach change based on the type of reaction (eg. Stevens-Johnson syndrome vs DRESS)?
How would you address maintenance (if any) post-transplant?
Would you consider pomalidomide for use in future lines of therapy?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Winship Cancer Institute of Emory University
Answered on
A rash with lenalidomide occurs in up to a third of patients exposed, and it's likely that dose corresponds directly with rash severity. While excellent desensitization protocols appear effective (PMID 31400463), most of us want to be able to deal with this with a phone call or text message that inc...
Join for free or sign in to see the full answer